Pear Therapeutics

Antoun Nabhan

J.D.

Antoun has experience leading the corporate development and/or finance functions at several successful biotechnology and medical device companies.

Antoun Nabhan was Vice President of Corporate Development at Raptor Pharmaceuticals, Inc., where he oversaw licensing and strategic transactions prior to Raptor’s acquisition by Horizon Pharmaceutics. He led Raptor’s acquisition of Tripex, Inc., adding to the company’s portfolio a product now approved for treatment of bacterial infections of the lung and marketed as Quinsair(R). Prior to joining Raptor, he served at Capnia, Inc. as VP of Corporate Development, where he managed their November 2014 IPO. Before Capnia, Antoun was a Senior Director in Onyx Pharmaceuticals’ Corporate Development and Strategy group. While there, he had responsibility for for multiple inbound and outbound transactions, including the acquisition of Proteolix, Inc. This added to Onyx’s portfolio a product now approved for treatment of multiple myeloma and marketed as Kyprolis(r) (carfilzomib). Prior to Onyx, he was a founding executive of three private biotechnology companies, Presidio Pharmaceuticals, Inc. Incellico, Inc., and Convivia. From 2001-2006 he served in positions of increasing responsibility with Sagamore Bioventures, where he led investments in private and public biotechnology companies. Antoun received a B.A. from the University of Chicago and a J.D. from Harvard Law School. He has served on the Board of Directors of BayBio, Presidio Pharmaceuticals, and Cellerant, Inc., as well as the Mayor’s Biotech Advisory Council under San Francisco Mayor Gavin Newsom.

When not doing deals, Antoun enjoys racing and collecting cars, and cooking for his family and friends.

Back